What is Merck & Co.'s noncontrolling interests in subsidiaries?

Merck & Co. (MRK) reported noncontrolling interests in subsidiaries of $53M in Q1 2026.

How has Merck & Co.'s noncontrolling interests in subsidiaries changed year-over-year?

Merck & Co.'s noncontrolling interests in subsidiaries decreased by 18.5% year-over-year, from $65M to $53M.

What is the long-term trend for Merck & Co.'s noncontrolling interests in subsidiaries?

Over 5 years (2020 to 2025), Merck & Co.'s noncontrolling interests in subsidiaries has grown at a -8.4% compound annual growth rate (CAGR), from $87M to $56M.

Merck & Co. MRK Noncontrolling interests in subsidiaries

Noncontrolling interests in subsidiaries at other companies

Bristol-Myers SquibbBMY

$34M-42.4%

PfizerPFE

——

AbbottABT

——

Gilead SciencesGILD

——

Roivant SciencesROIV

——

Royalty PharmaRPRX

——

Other financials

Income statement

See full

Revenue$16.3B+4.9%

Gross profit$12.1B-0.2%

Net income-$4.2B-183%

EPS (diluted)-$1.72-186%

Balance sheet

See full

Cash & equivalents$5.4B-38.2%

Total debt$49.1B+35.8%

Total equity$45.9B-5.1%

Total assets$128.69B+11.8%

Cash flow

See full

Operating cash flow$3.9B+56.7%

CapEx$991.0M-25.4%

Free cash flow$2.9B+150%

Valuation

See full

Market cap$285.12B+31.2%

Enterprise value$328.82B+34.2%

P/E31.9×+19.4×

P/S4.3×+0.9×

Profitability

See full

Gross margin73.9%-2.5pp

Net margin13.6%-13.7pp

Returns & leverage

See full

Return on equity19%-20.3pp

Debt / equity1.1×+0.3×

Current ratio1.3×-0.1×

Where this comes from

Reported directly by Merck & Co. in its filing.

Tagged under the XBRL concept us-gaap:MinorityInterest.

The official record: Merck & Co.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Merck & Co.'s noncontrolling interests in subsidiaries.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Merck & Co.'s noncontrolling interests in subsidiaries?: Merck & Co. (MRK) reported noncontrolling interests in subsidiaries of $53M in Q1 2026.
How has Merck & Co.'s noncontrolling interests in subsidiaries changed year-over-year?: Merck & Co.'s noncontrolling interests in subsidiaries decreased by 18.5% year-over-year, from $65M to $53M.
What is the long-term trend for Merck & Co.'s noncontrolling interests in subsidiaries?: Over 5 years (2020 to 2025), Merck & Co.'s noncontrolling interests in subsidiaries has grown at a -8.4% compound annual growth rate (CAGR), from $87M to $56M.